[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356500-105":59,"doc-detail-356500-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mechanistic-insights-into-a-novel-gpx4-inhibitor-compound-ai-3p-reversing-cisplatin-resistance-in-ovarian-cancer-cells","Mechanistic insights into a novel GPX4 inhibitor Compound AI-3p - reversing cisplatin resistance in ovarian cancer cells","","Ferroptosis is linked to chemotherapy resistance, and pharmacologically inducing ferroptosis can reverse drug resistance. The study focuses on GPX4-dependent signaling as a central regulator of ferroptosis. A novel GPX4 inhibitor, Compound AI-3p, was designed by linking an isoxazole pharmacophore to an anthraquinone core and assessed for activity against cisplatin (DDP)-resistant ovarian cancer cells. AI-3p inhibited GPX4/GSH signaling, promoting ROS production, lipid peroxidation, iron accumulation, labile iron pool buildup, and GSH depletion, supporting ferroptosis as a mechanism.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mechanistic-insights-into-a-novel-gpx4-inhibitor-compound-ai-3p-reversing-cisplatin-resistance-in-ovarian-cancer-cells/356500/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mechanistic-insights-into-a-novel-gpx4-inhibitor-compound-ai-3p-reversing-cisplatin-resistance-in-ovarian-cancer-cells/356500.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this research address in ovarian cancer treatment?","Question",{"text":112,"@type":113},"It addresses cisplatin resistance in ovarian cancer, where many patients relapse after platinum-based chemotherapy. The work aims to identify a compound that can counter this resistance by triggering ferroptosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was Compound AI-3p designed and what role does it target?",{"text":117,"@type":113},"Compound AI-3p was designed as a novel GPX4 inhibitor by linking an isoxazole pharmacophore to an anthraquinone core. It targets the GPX4 pathway that regulates ferroptosis.",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular and cellular mechanisms support AI-3p’s ferroptosis-inducing effect?",{"text":121,"@type":113},"Mechanistic experiments indicate GPX4/GSH axis inhibition, leading to increased ROS production, lipid peroxidation, iron ion and labile iron pool accumulation, and reduced GSH levels. These changes are consistent with ferroptosis activation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356500,1790168506,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Wang et al. Journal of Ovarian Research (2026) 19:104 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-026-02007-y](https://doi.org/10.1186/s13048-026-02007-y)  \nRESEARCH Open Access  \nMechanistic insights into a novel GPX4  inhibitor Compound AI-3p reversing cisplatinresistance in ovarian cancer cells  \nBingyu Wang1†, Dan Li2†, Linfang Lai2†, Ying Lu3, Ting-an Wang4,5, Jiaxing Song1, Pingzhen Wei1, Huaxin Hou2*†, Mingyuan Zhang1,6*† and Chunmiao Wang1*†  \nAbstract  \nBackground Ferroptosis has been correlated with the cancer chemotherapy resistance, and inducing ferroptosis has been demonstrated to reverse drug resistance. The GPX4-mediated signaling pathway is one of the most central pathways regulating ferroptosis. However, most currently available GPX4 inhibitors are covalent inhibitors, with limited structural diversity.  \nResults Here, we explored the potential and related molecular mechanisms of Compound AI-3p, a novel GPX4 inhibitor designed by linking an isoxazole pharmacophore to an anthraquinone core, for the treatment of cisplatin (DDP)-resistant ovarian cancer. Compound AI-3p showed significant cytotoxicity against DDP-resistant ovarian cancer cells (SKOV3/DDP), with a higher selectivity index against SKOV3/DDP and lower cytotoxicity against normal ovarian epithelial cells (IOSE80) than DDP. Molecular docking revealed that AI-3p forms a hydrogen bond with Leu130 in the catalytically active tetramer of GPX4, as well as carbon-hydrogen bonds with Sec 46, Gln81, and Lys135 . Further validation via molecular dynamics simulations and Cellular Thermal Shift Assay (CETSA) confirmed that AI-3p can form a stable complex with GPX4 . Mechanistic study revealed that Compound AI-3p could trigger the ferroptosis via inhibition of the GPX4/GSH axis, inducing reactive oxygen species (ROS) production, Lipid peroxidation, iron ion accumulation, Labile Iron Pool accumulation (LIP) accumulation, and a reduction in GSH content.  \nConclusions This study identifies Compound AI-3p as a novel GPX4 inhibitor that triggers ferroptosis, offering a potential breakthrough in the development of future drugs to combat cisplatin-resistant ovarian cancer development.  \n\n| †Bingyu Wang, Dan Li and Linfang Lai contributed equally to this work. |\n| --- |\n| †Chunmiao Wang, Huaxin Hou and Mingyuan Zhang share senior corresponding authors. |\n\n*Correspondence:  \nHuaxin Hou [houhuaxin@stu.gxmu.edu.cn](houhuaxin@stu.gxmu.edu.cn)[ ](houhuaxin@stu.gxmu.edu.cn)Mingyuan Zhang [Bio_MYZhang@163.com](Bio_MYZhang@163.com)[ ](Bio_MYZhang@163.com)Chunmiao Wang [wcm201910149@sr.gxmu.edu.cn](wcm201910149@sr.gxmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nWang et al. Journal of Ovarian Research (2026) 19:104 Page 2 of 18  \nKeywords GPX4, Compound AI-3p, Ferroptosis, Cisplatin-resistance, Ovaria","cbCaiqitwReYtOvg","https://ap.wps.com/l/cbCaiqitwReYtOvg","pdf",11543106,18,"English","# Abstract\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What problem does this research address in ovarian cancer treatment?\",\"answer\":\"It addresses cisplatin resistance in ovarian cancer, where many patients relapse after platinum-based chemotherapy. The work aims to identify a compound that can counter this resistance by triggering ferroptosis.\"},{\"question\":\"How was Compound AI-3p designed and what role does it target?\",\"answer\":\"Compound AI-3p was designed as a novel GPX4 inhibitor by linking an isoxazole pharmacophore to an anthraquinone core. It targets the GPX4 pathway that regulates ferroptosis.\"},{\"question\":\"What molecular and cellular mechanisms support AI-3p’s ferroptosis-inducing effect?\",\"answer\":\"Mechanistic experiments indicate GPX4/GSH axis inhibition, leading to increased ROS production, lipid peroxidation, iron ion and labile iron pool accumulation, and reduced GSH levels. These changes are consistent with ferroptosis activation.\"}]","Mechanistic insights into a novel GPX4 inhibitor Compound AI-3p - reversing cisplatin resistance in ovarian cancer cells | PDF",1790125620,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5963f761b4a7eecf02ce60f864f92bf.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7889dfa59229f8f619e95ad70064654c.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8786502a29497dea669c888df22771a.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acdd9c3890a8740af62af39ea89a073c.webp",980,1306]